Sodium cyanoborohydride → HCID 86702116, compound
Reaction equation
[CH3:1][C:2]1([CH2:8][N:9]2[CH:13]=[C:12]([C:14]3[CH:19]=[CH:18][C:17]([NH:20][C:21]([CH:23]4[CH2:26][N:25]([C:27]5[N:28]=[N:29][C:30]([CH3:33])=[CH:31][CH:32]=5)[CH2:24]4)=[O:22])=[CH:16][CH:15]=3)[CH:11]=[N:10]2)[CH2:7][CH2:6][NH:5][CH2:4][CH2:3]1.[O:34]1[CH2:37][C:36](=O)[CH2:35]1.C([BH3-])#N.[Na+]>CO>[CH3:1][C:2]1([CH2:8][N:9]2[CH:13]=[C:12]([C:14]3[CH:15]=[CH:16][C:17]([NH:20][C:21]([CH:23]4[CH2:26][N:25]([C:27]5[N:28]=[N:29][C:30]([CH3:33])=[CH:31][CH:32]=5)[CH2:24]4)=[O:22])=[CH:18][CH:19]=3)[CH:11]=[N:10]2)[CH2:7][CH2:6][N:5]([CH:36]2[CH2:37][O:34][CH2:35]2)[CH2:4][CH2:3]1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
N-(4-(1-((4-Methylpiperidin-4-yl)methyl)-1H-pyrazol-4-yl)phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide was dissolved in methanol (3 ml) and treated with oxetan-3-one (0.022 ml, 0.338 mmol) and sodium cyanoborohydride (0.021 g, 0.338 mmol) and stiffed overnight. The mixture was concentrated, purified by normal phase chromatography, triturated with ether and concentrated to give the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.09 (s, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.64-7.58 (m, 2H), 7.56-7.49 (m, 2H), 7.29 (d, J=9.1 Hz, 1H), 6.80 (d, J=9.0 Hz, 1H), 4.51 (t, J=6.4 Hz, 2H), 4.40 (t, J=5.8 Hz, 2H), 4.20 (t, J=8.3 Hz, 2 H), 4.12 (dd, J=7.9, 6.1 Hz, 2H), 3.98 (s, 2H), 3.73 (tt, J=8.5, 6.1 Hz, 1H), 3.48-3.39 (m, 1H), 2.44 (s, 3 H), 2.42-2.33 (m, 2H), 2.16-1.99 (m, 2H), 1.58-1.46 (m, 2H), 1.30 (d, J=12.6 Hz, 2H), 0.89 (s, 3 H); MS (ESI(+)) m/e 502 (M+H)+.
Workup
- concentrationThe mixture was concentrated
- custompurified by normal phase chromatography
- customtriturated with ether
- concentrationconcentrated
Sources & evidence
- ORD record
- ord-aa278e550a9447f89394267aa310e561
- Source dataset
- uspto-grants-2015_03
- Patent number
- US08975398B2
Reaction notes
Loading…